CLINICAL RESPONSE AT WEEK 52 AND COSTS IN PATIENTS WITH RHEUMATOID ARTHRITIS USING BIOLOGICAL THERAPY IN A SPECIALIZED CENTER IN COLOMBIA

• Published in: Value in health Vol. 20; no. 5; p. A144
• Main Authors: Santos-Moreno, P, Villarreal, L, Aza, A, Jaimes, H, Jaimes, J, Castro, C, Buitrago-Garcia, D
• Format: Journal Article
• Language: English
• Published: Lawrenceville Elsevier Science Ltd 01.05.2017
• Subjects: Autoimmune diseases; Cost analysis; Disability; Early retirement; Epidemiology; Etanercept; Immunotherapy; Infliximab; Monoclonal antibodies; Normality; Patients; Productivity; Rheumatoid arthritis; Rituximab; Tumor necrosis factor-α; Colombia

OBJECTIVES: Rheumatoid Arthritis (RA) is a chronic autoimmune disease with a prevalence of 1% in general population. Due to the course of disease patients have progressive disability that causes productivity losses and early retirement leading to great expenses for society. Biological treatment for...